Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025

Key Takeaway: SI-BONE, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The company will host a fireside chat to discuss its innovations in treating sacropelvic disorders. Investors can listen to the live webcast and access an archived version for 90 days post-event. SI-BONE is recognized for its pioneering work in minimally invasive SI joint surgery.
Price reaction · baseline $16.42 (2025-08-26 close) · hit after-hours · clean, no other SIBN news in the window
day 0 close · peak
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is participating in a prestigious healthcare conference.
  • The company has a strong track record with over 130,000 procedures performed.
  • Management will engage with investors through a fireside chat.

Full Press Release Details

SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rdAnnual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link:Morgan Stanley 23rd Global Healthcare Conference. Live audio of the webcast will be available on the “Investors” section of the company’s website at:www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,600 physicians in performing a total of nearly 130,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 175 peer reviewed publications including four randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visitwww.si-bone.com.
SI-BONE,Sacropelvic Solutions,iFuse Implant System®, iFuse Bedrock Granite,andiFuse TORQ, are registered trademarks, andiFuse 3D, iFuse TORQ TNT, andiFuse INTRAare trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.

Frequently Asked Questions

When is SI-BONE's presentation at the conference?

SI-BONE's presentation is scheduled for September 9, 2025.

How can investors listen to the conference call?

Investors can register to listen at the provided link on SI-BONE's website.

What is the focus of SI-BONE's technology?

SI-BONE focuses on surgical treatments for sacropelvic disorders.

What is the iFuse Implant System?

The iFuse Implant System is a minimally invasive solution pioneered by SI-BONE.

Last updated: Aug 26, 2025